EN HU

Pályiné dr Krekk Zsuzsanna

Publication list

2026
1.
Gebriné Éles, K., Radó, S. I., Ujváriné Siket, A., Szelesné Árokszállási, A., Sárváry, A., Gáll, T., Pályiné Krekk, Z., Bene, Á., Helmeczi, G., Törő, V., Barabás, Á., Major, G., Tilki, Á., Rákóczi, I., Takács, P.: Preparation of the reliability and validity test of the Hungarian adaptation of the modified Simulation Effectiveness Tool (SET-M HU).
In: Medical simulation and international training ground for teaching and scientific experiences. Ed.: by Zdzisława Chmiel, Izabela Sałacińska, Aneta Lesiak, Rzeszów University Press, Rzeszów, 25-36, 2026.
2021
2.
Pályiné Krekk, Z.: Molekuláris gerontológia napjainkban.
Magy. gerontol. 13 (40), 116-126, 2021.
2011
3.
Roszik, J., Sebestyén, Z., Govers, C., Guri, Y., Szöőr, Á., Pályiné Krekk, Z., Vereb, G., Nagy, P., Szöllősi, J., Debets, R.: T-cell synapse formation depends on antigen recognition but not CD3 interaction: studies with TCR : zeta, a candidate transgene for TCR gene therapy.
Eur. J. Immunol. 41 (5), 1288-1297, 2011.
Journal metrics:
Q1 Immunology
D1 Immunology and Allergy
2008
4.
Pályiné Krekk, Z., Barok, M., Kovács, T., Saya, H., Nagano, O., Szöllősi, J., Nagy, P.: EGFR and ErbB2 are functionally coupled to CD44 and regulate shedding, internalization and motogenic effect of CD44.
Cancer Lett. 263 (2), 231-242, 2008.
Journal metrics:
Q2 Cancer Research
Q1 Oncology
5.
Szöllősi, J., Vereb, G., Barok, M., Pályiné Krekk, Z., Nagy, P.: Role of Egf receptor tyrosine kinases in breast cancer: a biophysical approach.
Cytometry B. 74B (6), 385, 2008.
6.
Fazekas, Z., Petrás, M., Fábián, Á. I., Pályiné Krekk, Z., Nagy, P., Damjanovich, S., Vereb, G., Szöllősi, J.: Two-sided fluorescence resonance energy transfer for assessing molecular interactions of up to three distinct species in confocal microscopy.
Cytom. Part A. 73 (3), 209-219, 2008.
Journal metrics:
Q3 Cell Biology
Q1 Histology
Q1 Pathology and Forensic Medicine
2007
7.
Pályiné Krekk, Z., Barok, M., Isola, J., Tammi, M., Szöllősi, J., Nagy, P.: Hyaluronan-induced masking of ErbB2 and CD44-enhanced trastuzumab internalisation in trastuzumab resistant breast cancer.
Eur. J. Cancer. 43 (16), 2423-2433, 2007.
Journal metrics:
Q1 Cancer Research
Q1 Oncology
8.
Barok, M., Isola, J., Pályiné Krekk, Z., Nagy, P., Juhász, I., Vereb, G., Kauraniemi, P., Kapanen, A. I., Tanner, M., Vereb, G., Szöllősi, J.: Trastuzumab causes antibody-dependent cellular cytotoxicity-mediated growth inhibition of submacroscopic JIMT-1 breast cancer xenografts despite intrinsic drug resistance.
Mol. Cancer Ther. 6 (7), 2065-2072, 2007.
Journal metrics:
Q1 Cancer Research
D1 Oncology
DEENK University of Debrecen
© 2012 University of Debrecen